



## EDAP Expands HIFU Business in South America

Jun 2, 2009 (GlobeNewswire via COMTEX News Network) --

Receives Ablatherm-HIFU Approval in Argentina

Signs Exclusive Distribution Agreements in Argentina, Brazil and Chile

LYON, France, June 2, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the Ministry of Health in Argentina has approved Ablatherm-HIFU (high-intensity focused ultrasound) as a minimally invasive treatment option for patients with localized prostate cancer. Argentina closely follows Brazil as the latest country in South America to approve the device.

As part of EDAP's strategy to expand Ablatherm-HIFU in South America, EDAP has signed exclusive distribution agreements with experienced and dedicated partners in Argentina, Brazil and Chile to drive adoption of Ablatherm in the region as a proven therapeutic option for patients with prostate cancer. The Company's partners will include Jorge Litter in Argentina, H. Strattner in Brazil and UMS in Chile, all covering the largest markets in South America for localized prostate cancer.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "Our distribution partners are proven experts in distributing high technology medical devices in South America and have been performing successfully in the medical field and specifically in urology for years. We strongly believe they are the right partners to develop and build our presence in these countries as part of an ongoing effort to drive geographic expansion of our minimally-invasive HIFU option to patients with localized prostate cancer. Several clinical institutions have been showing strong interest in offering Ablatherm-HIFU to their patients and we are very enthusiastic to now provide them with a solution."

Mr. Oczachowski continued, "We are very pleased by the growing adoption and global expansion of Ablatherm-HIFU, particularly in South America with our entrance into new markets in Argentina and Brazil. These recent approvals mark a clear milestone for our technology as Ablatherm-HIFU gains further traction as a proven non-invasive therapeutic solution for prostate cancer."

### About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT US clinical Study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit <http://www.edap-tms.com>, <http://www.hifu-planet.com> and <http://www.pcaresearch.com>.

### Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

This news release was distributed by GlobeNewswire, [www.globenewswire.com](http://www.globenewswire.com)

SOURCE: EDAP TMS SA

EDAP TMS SA

Blandine Confort, Investor Relations / Legal Affairs  
+33 4 72 15 31 72

[bconfort@edap-tms.com](mailto:bconfort@edap-tms.com)

The Ruth Group

Investors:

Nick Laudico

646-536-7030

[nlaudico@theruthgroup.com](mailto:nlaudico@theruthgroup.com)

R.J. Pellegrino

646-536-7009

[rpellegrino@theruthgroup.com](mailto:rpellegrino@theruthgroup.com)

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX